StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Prime Medicine (PRME)

Fri, 10 Jul 2026 06:52:53 -0400

H.C. Wainwright analyst Arthur He reiterated a Buy rating and $8.00 price target on Prime Medicine (NASDAQ: PRME).

The analyst commented: "On July 8, Prime Medicine announced a positive, binding resolution of its arbitration with Beam Therapeutics over the parties' 2019 Collaboration and License Agreement. The arbitration tribunal declared that PM647, Prime's investigational prime editor for alpha-1 antitrypsin deficiency (AATD), falls within Prime’s “Field” as defined by the agreement, and that Prime owes no monetary damages to Beam. We view this as a clean, favorable outcome for the company. Critically, the ruling also eliminates a binary downside risk, as an adverse

TD Cowen on Prime Medicine (PRME): 'We continue to view PRME as undervalued for the platform’s potential'

Wed, 08 Jul 2026 12:30:17 -0400

TD Cowen analyst Joseph Thome reiterated a Buy rating on Prime Medicine (NASDAQ: PRME).

The analyst comments "PRME announced a positive binding arbitration resolution with BEAM over PM647 in AATD, confirming PM647 is in PRME’s field with no monetary damages. This removes a key investor overhang and clears the path for a Q3:26 filing, with initial data in 2027. We continue to view PRME as undervalued for the platform’s potential. Buy. PRME announced a positive, binding resolution of its previously disclosed arbitration with Beam Therapeutics, with the tribunal declaring that PM647 falls within PRME’s “Field” under the companies’ 2019 Collaboration and

TD Cowen on Prime Medicine (PRME): 'We continue to view PRME as undervalued for the platform’s potential'

Wed, 08 Jul 2026 12:30:17 -0400

TD Cowen analyst Joseph Thome reiterated a Buy rating on Prime Medicine (NASDAQ: PRME).

TD Cowen on Prime Medicine (PRME): 'We continue to view PRME as undervalued for the platform’s potential'

Wed, 08 Jul 2026 12:30:17 -0400

TD Cowen analyst Joseph Thome reiterated a Buy rating on Prime Medicine (NASDAQ: PRME).

TD Cowen on Prime Medicine (PRME): 'We continue to view PRME as undervalued for the platform’s potential'

Wed, 08 Jul 2026 12:30:17 -0400

TD Cowen analyst Joseph Thome reiterated a Buy rating on Prime Medicine (NASDAQ: PRME).

BofA Securities Comments on Beam Therapeutics Inc (BEAM) Amid Selloff

Wed, 08 Jul 2026 11:32:20 -0400

BofA Securities analyst Alec W. Stranahan reiterated a Buy rating and $47.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).

The analyst comments "The arbitration resolution (in favor of Prime Medicine, uncovered) in our view has limited impact to Beam as the ruling narrowly applies to PM647 rather than the overall prime editing estate. For context, Beam filed an AAA arbitration demand on April 16, 2025 alleging breach of the 2019 collaboration and license agreement, failure to transfer technical information, trade secret misappropriation and related business torts; Prime filed its own demand on April 18, 2025 seeking confirmation that its AATD

BofA Securities Comments on Beam Therapeutics Inc (BEAM) Amid Selloff

Wed, 08 Jul 2026 11:32:20 -0400

BofA Securities analyst Alec W. Stranahan reiterated a Buy rating and $47.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).

BofA Securities Comments on Beam Therapeutics Inc (BEAM) Amid Selloff

Wed, 08 Jul 2026 11:32:20 -0400

BofA Securities analyst Alec W. Stranahan reiterated a Buy rating and $47.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).

BofA Securities Comments on Beam Therapeutics Inc (BEAM) Amid Selloff

Wed, 08 Jul 2026 11:32:20 -0400

BofA Securities analyst Alec W. Stranahan reiterated a Buy rating and $47.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).

Form 8-K Prime Medicine, Inc. For: Jul 06

Wed, 08 Jul 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260708/26744590.html

Form 8-K Prime Medicine, Inc. For: Jul 06

Wed, 08 Jul 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260708/26744590.html

Prime Medicine wins arbitration against Beam Therapeutics over PM647

Wed, 08 Jul 2026 08:00:31 -0400

Prime Medicine, Inc. (Nasdaq: PRME) announced that an arbitration tribunal ruled in its favor in a dispute with Beam Therapeutics, Inc. over rights to develop its investigational gene editing therapy PM647 for Alpha-1 Antitrypsin Deficiency (AATD).

The tribunal declared that PM647 falls within Prime Medicine's "Field" as defined under a 2019 Collaboration and License Agreement between the two companies, meaning Prime Medicine did not breach the agreement. The company owes no monetary damages to Beam Therapeutics.

PM647 uses a lipid nanoparticle to correct the E342K mutation in the SERPINA1 gene, the most common disease-causing mutation in AATD. In humanized mouse models, the

Prime Medicine wins arbitration against Beam Therapeutics over PM647

Wed, 08 Jul 2026 08:00:31 -0400

PM647 uses a lipid nanoparticle to correct the E342K mutation in the SERPINA1 gene, the most common disease-causing mutation in AATD. In humanized mouse models, the

Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics

Wed, 08 Jul 2026 08:00:00 -0400

-- Arbitration tribunal declared that PM647 is within Prime Medicine’s “Field”, confirming Prime Medicine’s right to develop and commercialize PM647 in AATD --

-- Prime Medicine owes no monetary damages to Beam Therapeutics --

-- Prime Medicine plans to submit an IND and/or CTA filing for PM647 in Q3 2026, initial clinical data expected in 2027 --

CAMBRIDGE, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced a positive, binding

Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics

Wed, 08 Jul 2026 08:00:00 -0400

-- Arbitration tribunal declared that PM647 is within Prime Medicine’s “Field”, confirming Prime Medicine’s right to develop and commercialize PM647 in AATD --

-- Prime Medicine owes no monetary damages to Beam Therapeutics --

-- Prime Medicine plans to submit an IND and/or CTA filing for PM647 in Q3 2026, initial clinical data expected in 2027 --

H.C. Wainwright Upgrades Prime Medicine (PRME) to Buy

Mon, 29 Jun 2026 06:47:09 -0400

(Updated - June 29, 2026 6:47 AM EDT)

H.C. Wainwright analyst Arthur He upgraded Prime Medicine (NASDAQ: PRME) from Neutral to Buy with a price target of $8.00.

The analyst comments "WD program’s CTA cleared in New Zealand. On June 18, Prime Medicine announced that New Zealand's Medicines and Medical Devices Safety Authority (Medsafe) cleared the Clinical Trial Application (CTA) for PM577a, an LNP-formulated Prime Editor designed to treat Wilson’s Disease (WD) patients with the H1069Q mutation in ATP7B. The H1069Q mutation is the most prevalent WD variant in the U.S. and Europe, accounting for 30-50% of cases. We view the clearance

H.C. Wainwright Upgrades Prime Medicine (PRME) to Buy

Mon, 29 Jun 2026 06:47:09 -0400

(Updated - June 29, 2026 6:47 AM EDT)

H.C. Wainwright analyst Arthur He upgraded Prime Medicine (NASDAQ: PRME) from Neutral to Buy with a price target of $8.00.

FDA grants RMAT designation to Prime Medicine's CGD therapy PM359

Mon, 22 Jun 2026 08:02:18 -0400

Prime Medicine, Inc. (Nasdaq: PRME) announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to PM359, an investigational autologous gene-edited hematopoietic stem cell therapy for p47phox-deficient chronic granulomatous disease (CGD).

The designation was based on Phase 1/2 clinical data, including results published in The New England Journal of Medicine in December 2025. That data showed a single dose of PM359 produced rapid engraftment and restoration of immune cell function in both treated patients, with neutrophil activity above the level associated with clinical benefit.

RMAT designation, established under the 21st Century Cures Act, is intended for

Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

Mon, 22 Jun 2026 08:00:00 -0400

-- RMAT designation granted based on Phase 1/2 clinical data, including results previously published in The New England Journal of Medicine, demonstrating PM359’s potential to address unmet need in p47^phox-deficient CGD --

-- Designation enables early and intensive FDA engagement, and provides eligibility for rolling and priority Biologics License Application review --

-- PM359 now holds RMAT, Fast Track, Orphan Drug, and Rare Pediatric Disease Designations --

CAMBRIDGE, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time

Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

Mon, 22 Jun 2026 08:00:00 -0400

-- Designation enables early and intensive FDA engagement, and provides eligibility for rolling and priority Biologics License Application review --

-- PM359 now holds RMAT, Fast Track, Orphan Drug, and Rare Pediatric Disease Designations --

CAMBRIDGE, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time

Prime Medicine (PRME) Reiterated at Market Outperform by Citizens as Trial Announced

Mon, 22 Jun 2026 04:16:17 -0400

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $6.00 price target on Prime Medicine (NASDAQ: PRME).

The analyst commented, "PRME is focused on large in-vivo indications that can provide clear value for prime editing. We believe following the upcoming AATD arbitration (late July), the story will refocus on the technology and clinical execution with FiH data in 2027. PRME hosted a WD KOL event and highlighted the sustained need in patients that are barely served by the current SoC. Clinical-stage gene therapies are also de-risking the approach, despite the AAV-based shortcomings."

For an analyst ratings summary and ratings history on

Prime Medicine gets New Zealand clearance for Wilson disease gene therapy

Thu, 18 Jun 2026 08:03:44 -0400

Prime Medicine, Inc. (Nasdaq: PRME) announced that New Zealand's Medicines and Medical Devices Safety Authority (Medsafe) has cleared the company's Clinical Trial Application for PM577a, an investigational Prime Editing therapy targeting Wilson Disease (WD).

According to the company, the clearance marks the first clinical authorization for an in vivo Prime Editing therapy from Prime Medicine. The company said it expects to initiate a Phase 1/2 clinical trial in the second half of 2026, with initial clinical data anticipated in 2027.

PM577a targets the H1069Q mutation in the ATP7B gene, which the company states accounts for approximately 30–50% of WD-associated variants in the

Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease

Thu, 18 Jun 2026 08:00:00 -0400

-- First clinical authorization for an in vivo Prime Editing therapy from Prime Medicine --

-- PM577a targets the H1069Q mutation in the ATP7B gene, the most prevalent WD-causing allele in North America and Europe --

-- Initiation of Phase 1/2 clinical trial expected in second half of 2026; initial clinical data expected in 2027 --

-- Shared LNP delivery platform may enable rapid expansion into additional WD pathogenic variant populations; most advanced follow-on candidate targets the R778L mutation frequently found in East Asian populations --

CAMBRIDGE, Mass., June 18,

Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease

Thu, 18 Jun 2026 08:00:00 -0400

-- First clinical authorization for an in vivo Prime Editing therapy from Prime Medicine --

-- PM577a targets the H1069Q mutation in the ATP7B gene, the most prevalent WD-causing allele in North America and Europe --

-- Initiation of Phase 1/2 clinical trial expected in second half of 2026; initial clinical data expected in 2027 --

CAMBRIDGE, Mass., June 18,

Prime Drink Group raises up to $2.2 million in private placement

Fri, 12 Jun 2026 18:30:14 -0400

Prime Drink Group Corp. (CSE: PRME) announced a non-brokered private placement offering to raise between $1.2 million and $2.2 million through the sale of units priced at $10,000 each.

Each unit consists of 200,000 common shares at a deemed price of $0.05 per share and 200,000 transferable share purchase warrants. The warrants allow holders to purchase common shares at $0.10 per share for one year from the issuance date.

The offering will result in the issuance of 24 million to 44 million common shares and an equal number of warrants, depending on subscription levels. The securities are subject to a four-month and